Alexion

Overview

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

US/UNB-a/0460

Patient Assistance Programs

• OneSource^TM is a complimentary, personalized patient support program offered by Alexion and tailored to the specific needs of people living with aHUS (atypical Hemolytic Uremic Syndrome), PNH (Paroxysmal Nocturnal Hemoglobinuria), gMG (generalized Myasthenia Gravis), NMOSD (Neuromyelitis Optica Spectrum Disorder), HPP (Hypophosphatasia), LAL-D (Lysosomal Acid Lipase Deficiency), and NF1 (Neurofibromatosis Type 1). For more information, please call 1-888-765-4747
• PNH Source Facebook page for patients and caregivers with PNH
• aHUS Source Facebook page for patients and caregivers with aHUS

For order inquires, customer operations, case management, medical information, product complaints, or to inquire about the REMS (Risk Evaluation and Mitigation Strategy) programs, please call 1-888-765-4747.